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ABSTRACT

INTRODUCTION

The Drug-Gene Interaction Database (DGIdb, www.
dgidb.org) is a web resource that provides information on drug-gene interactions and druggable genes
from publications, databases, and other web-based
sources. Drug, gene, and interaction data are normalized and merged into conceptual groups. The
information contained in this resource is available
to users through a straightforward search interface, an application programming interface (API), and
TSV data downloads. DGIdb 4.0 is the latest major
version release of this database. A primary focus
of this update was integration with crowdsourced
efforts, leveraging the Drug Target Commons for
community-contributed interaction data, Wikidata to
facilitate term normalization, and export to NDEx
for drug-gene interaction network representations.
Seven new sources have been added since the last
major version release, bringing the total number of
sources included to 41. Of the previously aggregated
sources, 15 have been updated. DGIdb 4.0 also includes improvements to the process of drug normalization and grouping of imported sources. Other
notable updates include the introduction of a more
sophisticated Query Score for interaction search results, an updated Interaction Score, the inclusion of
interaction directionality, and several additional improvements to search features, data releases, licensing documentation and the application framework.

Originally released in 2013, the Drug–Gene Interaction
database (DGIdb) (1) serves as a central aggregator of information on drug-gene interactions and druggability from
multiple diverse sources. The subsequent major updates to
DGIdb 2.0 (2) (in 2016) and 3.0 (3) (in 2018) included improvements to the user interface and search response times,
the addition of an API, the introduction and improvement
of gene and drug grouping methods, and the expansion of
source content through the inclusion of new sources and updates of existing sources. Since the release of DGIdb 3.0,
many of the existing sources have been substantially updated and new sources have become available. Here we describe changes made for our most recent major version release, DGIdb 4.0. In this release, we have made an effort
to integrate crowdsourced data and sources in several areas, including the addition of the crowdsourced Drug Target Commons (4) as a drug-gene interaction source, and
the use of the open, community-curated Wikidata (5) resource for drug normalization. We also illustrate the value
of our integration efforts in downstream community tools,
through the incorporation of our data into NDEx (6). To
keep content offered by DGIdb current, we have developed
additional automatic update routines for multiple sources
and implemented a new background job management system (Sidekiq, sidekiq.org) for routine job scheduling. Finally, DGIdb 4.0 focuses on numerous improvements of
search results, including new and updated scores for interaction search results and improved drug normalization
routines.
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Integration with crowdsourced efforts

New and updated sources
In an effort to ensure that DGIdb offers diverse and contemporary information, we have updated and added several sources to DGIdb 4.0. In addition to the previously
mentioned Drug Target Commons (4), we now also include
COSMIC (15) as a new source of drug-gene interaction
data (Supplementary Table S1). COSMIC also serves as
an additional source of curated Drug Resistance gene category claims. Other new gene category sources include the
Tempus xT (16) panel of actionable cancer therapy target
genes, a list of the top priority genes from the Illuminat-
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A primary focus of the DGIdb 4.0 release is the inclusion
and utilization of crowdsourced efforts in several aspects
of our database. The utility of our database begins with
importing relevant drug, gene, and drug-gene interaction
records (called claims) from outside resources. We normalize and sort these claims into conceptual groups, and make
these concepts searchable via a web application and API.
We also export data for bulk download and use with external resources (Figure 1). In this update, we extend these
features by integration with crowdsourced drug-gene interaction claims, normalizing drug terms, and integrating with
external resources.
For drug–gene interaction claims, we have added Drug
Target Commons as a new source in DGIdb 4.0 (Figure 1). Drug Target Commons provides an extensive curated database of crowdsourced drug-gene interactions,
from which we added a total of 23 879 interaction claims.
This represents ∼24% (23 879/100 273) of the total interaction claims in DGIdb.
For drug normalization, we now use a Wikidata normalizer in addition to a ChEMBL (7) normalizer from
the thera-py python package (Figure 1; additional detail
in Drug Grouping Improvements section). Wikidata serves
as a source of collaborative, crowdsourced drug concepts,
and has allowed us to improve normalization in cases
where ChEMBL normalization failed. For example, concepts representing the terms annamycin, N-methyl scopolamine and Debio 1347 are all found in Wikidata but not
ChEMBL.
Finally, we have integrated DGIdb with the Network
Data Exchange (NDEx) (6), a community resource that allows sharing and publishing of biological data in a networkbased format. For DGIdb, export of DGIdb data to the
NDEx platform provides a resource for the visual representation of relationships and interactions between drugs
and genes present in our database, allowing users to visually explore a global network of drugs and gene interactions of interest. NDEx TSVs are generated monthly and
automatically uploaded to the NDEx server to keep the
DGIdb network in NDEx up-to-date (Figure 1). NDex is
the latest in a number of community resources that have integrated DGIdb. Existing data clients include GeneCards
(8), BioGPS (9), CancerTracer (10), Gene4Denovo (11), SLBioDP (12), TargetDB (13) and OncoGemini (14), among
others.

ing the Druggable Genome (IDG) (17) Initiative, the Human Protein Atlas (18), the Oncomine (19) clinical cancer
biomarker assay, and understudied targets of the IDG program from Pharos (20) (Supplementary Table S1). From
these new sources, we have added 23 916 new drug-gene
interaction claims and 8478 new druggable gene category
claims (Figure 2). In total, we have added two new sources
of drug-gene interactions and five new sources of druggable
gene category claims. DGIdb 4.0 now has 100 273 interaction claims and 33 577 druggable gene category claims.
In total, there are now 10 606 druggable genes and 54 591
drug–gene interactions, which cover 41 102 genes and 14
449 drugs, within the DGIdb.
We have also updated multiple sources including large,
well-curated sources such as DrugBank (21), Guide to Pharmacology (22), Gene Ontology (23,24), OncoKB (25), PharmGKB (26), and the Therapeutic Target Database (27)
(Figure 2, Supplementary Table S1). To facilitate routine
updates, the importer for PharmGKB has been updated
to an online importer that can be run periodically using
DGIdb’s new automated job scheduling system (see Technology Improvements). Similarly, Pharos (20), one of our
new sources, has been implemented as an online updater. Of
the 41 sources in DGIdb, 12 sources are now imported using
the online updater format, including Entrez (28), the core
source of gene concepts for gene grouping in DGIdb, and
Ensembl (29), a key source of gene aliases. In DGIdb 4.0,
the number of genes imported from Entrez has increased
from 41 102 to 42 851 and Ensembl has been updated from
version 90 38 to version 101 38. We have also migrated several older sources from our original domain-specific language (DSL) importers to the improved TSV importer style
implemented in DGIdb 3.0.
In DGIdb 4.0, the database structure and presentation model was updated to allow sources to be imported
with multiple source types. This change enables merging
of sources that were previously duplicated for each independent claim type (drug, gene, interaction, druggable gene
category). For example, we previously imported both interaction claims and druggable gene category claims from
Guide to Pharmacology (22) with two separate importers
which created two separate sources (GuideToPharmacologyInteractions and GuideToPharmacologyGenes, respectively). With this update, the import of interaction claims
and druggable gene category claims is now handled by one
importer and only a single source (GuideToPharmacology)
is created. This is intended to simplify and unify claim
sources to aid in downstream interpretation. Additionally,
supporting sources that have multiple source types enables
easy extension to collect more informative claim type information. For example, some claims from CIViC (30) can be
imported with the additional categories of drug resistance
and clinically actionable. This change results in an additional 150 druggable gene category claims being imported
from CIViC. Overall, these changes will increase the efficiency and accuracy of the process of importing and updating sources in DGIdb 4.0 compared to previous versions and will make it easier for users to evaluate individual
sources.
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Drug grouping improvements
Another notable change in the DGIdb 4.0 update is the improvement to drug grouping and normalization. Previously,
we grouped drug claims using a rule-based pairwise association approach. This process was cumbersome, requiring
a lengthy and complete re-grouping of all claims whenever
we updated sources in order to generate consistent group-

ings. We revised this approach by creating a normalization component independent of the claims aggregated by
DGIdb, that could be run on a per-source basis. When redesigning this part of DGIdb, we took steps to enable reuse
of this normalizer as a modular component for other resources. To this end, we leveraged and contributed to a drug
normalization service from the Variant Interpretation for
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Figure 1. Overview of main components of DGIdb. Data sources are imported from outside resources (over 40 as of DGIdb 4.0), normalized and grouped
with internal processes to prepare records to be displayed in DGIdb, and exported to TSV for download and integration with other resources. Process
management is handled by Sidekiq for automation of importing, normalization and grouping, and exporting. A subset of new data sources are highlighted
in green, a subset of updated pre-existing data sources are highlighted in blue. The updated sources highlighted in this figure are some of the sources that
have been updated through manual curation. Information on additional sources and their status in DGIdb 4.0 can be found in Figure 2 and Supplementary
Table S1. New features and technologies from DGIdb 4.0 are indicated with green dots, pre-existing features and technologies that have been updated are
indicated with blue dots. The drug-gene network graph shown in the bottom right is an example of the data visualizations available on NDEx. Abbreviations:
CMI = Caris Molecular Intelligence, FO = Foundation One, DTC = Drug Target Commons and HPA = Human Protein Atlas.
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Cancer Consortium (the ‘thera-py’ Python Package; source
code online at https://github.com/cancervariants/therapynormalization). Among our contributions to thera-py was
a normalizer for the Wikidata (5) resource, further enabling
community contributions to assist in concept normalization
both for DGIdb and other resources reliant upon the VICC
normalization services.
Drug claims from DGIdb were normalized using the
ChEMBL and Wikidata normalizers from thera-py. Rules
were written to formalize grouper behavior based upon
match characteristics of a query. Briefly, these rules prioritize matches to primary labels over aliases, exact case
over case-insensitive, and ChEMBL over other normalizers.
An algorithm for constructing a merged drug concept from
normalizer results was specified, enabling a standardized set
of aliases for a given concept identifier. Pseudocode for this
algorithm is provided (see Supplementary Data), and all implemented code is available on our public repository (see
Data Availability).
New Query Score and updated Interaction Score
One of the main features added in DGIdb 4.0 is the concept of a relative Query Score for interaction search results.
Previously, interaction search results displayed only a static
Interaction Score based on evidence of an interaction (i.e.
the number of publications and sources supporting an interaction claim). This Interaction Score did not take into
account whether the gene and drug involved in a given interaction were also part of a large number of other interactions
and, thus, had a low specificity that should be penalized. In
addition, when searching for a set of genes or drugs, the Interaction Score does not prioritize results with overlapping
interacting drugs or genes, which might be of more interest to the user, particularly in drug discovery and pathway
applications.

DGIdb 4.0 now provides a Query Score that is relative to
the search set and considers the overlap of interactions in
the result set. For interaction searches using a gene list, the
Query Score is calculated from the Evidence Scores (publications and sources), the number of genes from the search
set that interact with the given drug, and the degree to which
the drug has known interactions with other genes (Figure
3). Similarly, for interaction searches using a drug list, the
Query Score depends on the Evidence Scores (publications
and sources), the number of drugs from the search set that
interact with the given gene, and the degree to which the
gene has known interactions with other drugs (Figure 3).
In effect, this means that genes and drugs with many overlapping interactions in the search set will rank more highly,
with the caveat that drugs or genes involved in many interactions, in general, will have lowered scores (Figure 3).
Our static Interaction Score previously introduced in
DGIdb 3.0 (3) has been adjusted in DGIdb 4.0. The Interaction Score now mirrors the Query Score, except it is
unaffected by the queried gene or drug sets, instead relying
only on Evidence Scores and the degree to which both the
gene and drug are involved in other interactions (Figure 3).
Interaction Scores follow a long-tail distribution, indicative
of many highly promiscuous (31) drugs and genes, and relatively few well-supported, highly specific drug-gene interactions (Supplementary Figure S1).
The introduction of the relative Query Score provides
users with a score that gives a more intuitive ranking of
drugs or genes based on the search set of interest, allowing
the prioritization of drugs or genes that have overlapping,
specific interactions with the search set. Similarly, the improvements to the static Interaction Score provide a more
nuanced scoring system that takes into consideration the
number of interactions for a drug-gene pair, in addition
to the previous Evidence Scores, giving a more informative
static Interaction Score.
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Figure 2. DGIdb 4.0 content by source. The number of drug-gene interaction claims (first panel) and druggable gene categories (second panel) are separated
into three categories: sources that are new, sources that existed in the DGIdb previously but have been updated for 4.0, or sources that existed previously but
have not been updated. Abbreviations: CF = Clearity Foundation, CGI = Cancer Genome Interpreter, CMI = Caris Molecular Intelligence, DTC = Drug
Target Commons, FO = Foundation One, GO = Gene Ontology, GTP = Guide to Pharmacology, HPA = Human Protein Atlas, IDG = Illuminating the
Druggable Genome, JAX-CKB = JAX-Clinical Knowledgebase, MCG = My Cancer Genome, MSK = Memorial Sloan Kettering, OncoKB = Precision
Oncology Knowledge Base, TALC = Targeted Agents in Lung Cancer, TDG = The Druggable Genome, TEND = Trends in the Exploration of Novel
Drug targets and TTD = Therapeutic Target Database.
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Figure 3. Overview of DGIdb’s new Query scores and Interaction scores. (A) Schematic of how each of the new scores is calculated within DGIdb. Gene and
drug queries both return a Query Score that is dependent on the search terms. Each interaction has an Interaction Score that is calculated independently of
other search terms. (B) Example of a Query Score changing based on the terms searched. In the first panel, only MEK1 and MEK2 were searched and the
Query Score for the interaction between MEK1 and Cobimetinib was 8.09. In the second panel, BRAF and KRAS were added to the search query. These
both interact with Cobimetinib and thus raise the Query Score to 16.18. (C) Example of Interaction Score. The panel on the left shows the interaction
between ZEB1 and Salinomycin. This is the only interaction for Salinomycin and thus it has a high Interaction Score. The panel on the right shows the
interaction between ZEB1 and Doxorubicin. Doxorubicin is involved in 103 interactions within DGIdb and thus has a much lower Interaction Score. Note
that over time, as sources are updated and new claims are added, both Query Scores and Interaction Scores may change.

Nucleic Acids Research, 2021, Vol. 49, Database issue D1149

As sources are updated and additional interaction claims
are added to DGIdb, Interaction Scores and Query Scores
are subject to change as a result of the changing measure to
which Drug and Gene concepts interact with one another.
Query Scores are always variable, dependent upon the set
genes or drugs searched.

We have also added information on the directionality of interaction types to the interaction search results. Each interaction type in DGIdb now has an indicated directionality
of activating, meaning the interaction type mechanism has
an overall activating effect; inhibitory, meaning the interaction type mechanism has an overall inhibitory effect; or
n/a, meaning the directionality is unclear for the interaction type mechanism (Supplementary Table S2). Determination of the directionality for an interaction type was made
from mechanistic definitions provided by drug–gene interaction sources in which the interaction type was observed.
Where these definitions were not available, we instead relied upon community definitions of these interaction types.
These interaction directionalities are included on the UI for
interaction search results in parentheses next to the interaction type(s) listed for each interaction result (Supplementary Figure S2). While the directionality may be obvious for
some interaction types (e.g. activators are activating), some
interaction types are not immediately apparent (e.g. chaperones are activating) to those less familiar with mechanisms
of drug–gene interactions. Inclusion of directionality can
make it easier for users to distinguish interactions that are
more relevant for their purposes. For example, a user interested in exploring drugs that inhibit a particular gene will
look for drug-gene interactions with inhibitory directionality. Users are also able to limit their interaction search to
only interaction types of a desired directionality. Detailed
information on each interaction type, the definition of each
interaction type, and the directionality of each interaction
are also available on the DGIdb Interaction Types page
(https://dgidb.org/interaction types).
Search feature improvements
In DGIdb 4.0, we have introduced several updates related
to searching, search results, and information available on
the user interface. Among these are the addition of the option to search only cancer-specific sources (meaning sources
that report claims relating to cancer only), or diseaseagnostic sources (meaning sources that report claims relating to any disease, including cancer) for both interaction searches and druggable gene category searches. Cancerrelated searches are a major use-case for DGIdb and cancerspecific sources are well-represented among all sources,
with 13 cancer-specific drug-gene interaction sources and
five cancer-specific druggable gene category sources. However, DGIdb is not a cancer-specific resource and is intended to be utilized for non-cancer related research as
well. For drug-gene interactions, there are 4955 interactions supported by cancer-specific sources only, 48 341 interactions supported by disease-agnostic sources only, and
1,295 interactions are supported by both cancer-specific

Monthly data releases
DGIdb 3.0 implemented online updaters that imported
data from dynamic sources (such as CIViC (30), Guide to
Pharmacology (22), OncoKB (25), etc.) periodically, usually monthly. As a result, the static TSV data releases available on our Downloads page would quickly become outdated. For DGIdb 4.0, we have implemented monthly data
releases of these TSVs to coincide with monthly runs of the
online updaters, to ensure that TSVs available for download
reflect the most up to date information in our database. The
Downloads page now makes available the current Gene,
Drug, Interaction and Category TSVs as well as previous
monthly TSVs since the release of DGIdb 4.0. These serve
as de facto snapshots of the data in DGIdb over time.
Improved transparency and details on licensing of sources
In DGIdb 4.0, we have made a significant effort to update and improve the information we provide on licensing of sources imported into our database through manual curation of data license descriptions and references
for every source. This information is now readily available on the sources page. Since DGIdb 3.0, several existing sources have made changes to their licensing, making data from some sources more broadly available and
data from other sources more restricted. Notably, PharmGKB (26) has moved to a more permissive Creative Commons Attribution-ShareAlike 4.0 International License and
DrugBank (21) has adopted a custom non-commercial license. In contrast, OncoKB (25) has restricted API access
to registered/approved non-commercial research use only,
and JAX-CKB (32) has restricted API access to negotiated
licenses only. Both resources continue to provide access to
a portion of their data for free through their respective web
clients.
Application framework updates
To handle increased web traffic and integration with other
tools, we have upgraded DGIdb to Rails 6 (from Rails 5),
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Inclusion of interaction directionality

and disease-agnostic sources. Similarly, for druggable gene
categories, 233 genes have categories supported by cancerspecific sources only, 17 168 genes have categories supported by disease-agnostic sources only and 2804 genes have
categories supported by both cancer-specific and diseaseagnostic sources. These numbers show that although a sizable portion of the sources included in DGIdb are cancerspecific, those types of sources only represent a small proportion of the overall data.
Other improvements to search result features include the
addition of linkouts to specific interaction evidence, where
available. These will allow users to browse to the primary
source for an interaction claim which might provide additional information and context not captured by DGIdb.
Also, while we introduced drug and gene filters to the interaction search view in the last major update, we have had
several requests to define how these filters are implemented.
To address this lack of transparency on the UI, we have now
added a link to the FAQ page where these filters are now defined.
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SUMMARY AND FUTURE DIRECTIONS
With our most recent release, DGIdb has received significant improvements to source content, functionality such as
searching and grouping, and underlying application technology. We have significantly expanded the number of
records in our database through the addition of new sources
and updates of existing sources. Furthermore, we have improved our ability to maintain regular content updates
through the implementation of additional online importers
for several sources and the use of Sidekiq for automatic job
processing. We have revised our process for drug grouping
and normalization to be batched by resource and to leverage continual improvement through community contributions to the VICC thera-py normalizers and the Wikidata
public-domain crowdsourcing platform. Finally, several updates have been made to inform users of the relevance of
search results through information presented on the UI. We
have implemented more sophisticated notations of relative
and static interaction scores, improved the relevance of interaction source linkouts wherever possible, and included
the concept of directionality for interaction results.
Although the updates in DGIdb 4.0 have improved the
usability and content of our resource, we expect there will
still be a need for future improvements. One technology improvement on our roadmap is converging the public-facing
API with the internal code that powers the web views. Ultimately, we want the APIs available for general use to be the
same ones powering our HTML pages. This would provide
an even more fully featured API to end users while reducing
our overall maintenance burden by eliminating redundant
code. We are also evaluating the addition of information on
gene-gene relationships. As always, we plan to continue updating sources to online updaters where possible, and migrating TSV-based sources from the legacy DSL importers
to the TSV importers introduced in DGIdb 3.0.

DATA AVAILABILITY
DGIdb is an open access database and web interface (www.
dgidb.org) with open source code available on GitHub
(https://github.com/griffithlab/dgi-db) under the MIT license. We also provide data downloads for drug claims, gene
claims, and interaction claims on the website in addition to
a SQL data dump (http://dgidb.org/downloads). Information about the API and its endpoints can also be found on
the website (http://dgidb.org/api).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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upgraded to Ruby 2.6.5 (from Ruby 2.3), upgraded to PostgreSQL 12 (from PostgreSQL 9.6), and upgraded the server
to the latest Ubuntu LTS release (20.04). In addition to
the new features and performance benefits these upgrades
bring, they will ensure that we continue to remain on supported software versions that receive regular security updates.
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